Q4 2024 Earnings Call Transcript March 5, 2025 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.05 ...
Ocugen ( OCGN -3.41%) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...
Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis. TEL AVIV, Israel, (GLOBE NEWSWIRE) -- C ...
Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...
Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...
Vantage Specialty Chemicals, Inc., (Vantage) today announced that its VYCERIN™ API Glycerin, USP is listed on the Drug Master File (DMF-040171) with the U.S. Food and Drug Administration (FDA). This ...
Conor McGregor's recent social media activity suggests a potential move to the Bare Knuckle Fighting Championship, despite ...
Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration ...
as the UK biotech reports confirmatory phase 3 data ahead of an FDA filing later this month. The results of the FM71 trial of MED3000 showed that the topical gel formulation achieved a significant ...
but some patients – roughly 1% according to FDA estimates – don’t get the hoped-for benefit, while others are intolerant to the drugs. Sobi’s filing is based on the DISSOLVE I and II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback